Institut DERMed Clinical Skin Care

Products          Training          Spa

Sign InMy AccountCustomer ServiceShopping Cart

Distribution: 1-866-433-7633
Spa: 404-261-5199

Monday, 27 July 2009 13:12

Accutane is Off the Market

Rate this item
(0 votes)

Big news in the world of skincare is that Accutane – an effective, though controversial acne medicine – is going off the market.  The high cost of personal injury lawsuits has caused the makers of this potent drug to remove it from their offering of products.  Of course, the question now becomes – what is a viable alternative for patients and doctors in their battle against Acne Vulgaris?

One of the newest acne-fighting systems is the Isolaz system, a leading device-based acne therapy and the only FDA cleared treatment for Comedonal and Pustular Acne. The device is also cleared for the treatment of mild to moderate acne including Acne Vulgaris.

 

What is the technology behind the Isolaz system?

 

About Photopneumatic™ Technology
Photopneumatic Therapy that powers the Isolaz™ and Isolaz Pro™ system is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.

 

 

If you’re dealing with acne issues, please speak to your Institut’ DERMed esthetician about options for treatment.  Institut’ DERMed Founder Lyn Ross has had many years of personal experience with acne and has developed an acne-specific line of products to address this concern.